4.86
2.76%
-0.21
Precedente Chiudi:
$5.07
Aprire:
$5.05
Volume 24 ore:
122.23K
Relative Volume:
0.70
Capitalizzazione di mercato:
$92.37M
Reddito:
-
Utile/perdita netta:
$-22.38M
Rapporto P/E:
-3.1355
EPS:
-1.55
Flusso di cassa netto:
$-15.54M
1 W Prestazione:
-13.96%
1M Prestazione:
-35.89%
6M Prestazione:
-18.91%
1 anno Prestazione:
-39.29%
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Confronta NVCT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
NVCT | 4.8601 | 92.37M | 0 | -22.38M | -15.54M | -1.55 |
VRTX | 449.35 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 749.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.51 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.60 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia
Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St
Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat
Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com UK
Nuvectis pharma chairman buys $98,400 in common stock - Investing.com
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail
500: Something went wrong - Investing.com Canada
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Yahoo Finance
NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India
Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN
U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn
Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha
Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch
Nuvectis Pharma Inc trading resumes - TipRanks
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian
Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan
Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK
FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World
FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat
Analysts Offer Predictions for Nuvectis Pharma Q1 Earnings - Defense World
Roth Capital Comments on Nuvectis Pharma Q1 Earnings - MarketBeat
Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress - TipRanks
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Trend Tracker for (NVCT) - Stock Traders Daily
Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire
NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Marshall Wace LLP Has $214,000 Stock Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily
Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance
(NVCT) Trading Advice - Stock Traders Daily
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News
What's Going On With Nuvve Stock? - Benzinga
Rhumbline Advisers Has $3.18 Million Position in NVE Co. (NASDAQ:NVEC) - Defense World
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
BENTSUR RON | Chairman & CEO |
Nov 15 '24 |
Buy |
4.92 |
20,000 |
98,400 |
3,266,424 |
Carson Michael J. | Vice President, Finance |
Nov 07 '24 |
Sale |
8.16 |
2,755 |
22,478 |
87,918 |
BENTSUR RON | Chairman & CEO |
May 14 '24 |
Buy |
6.74 |
1,940 |
13,076 |
3,246,424 |
BENTSUR RON | Chairman & CEO |
May 10 '24 |
Buy |
6.40 |
2,000 |
12,800 |
3,244,484 |
Poradosu Enrique | Chief Science & Business Off |
May 10 '24 |
Buy |
6.29 |
500 |
3,145 |
1,504,319 |
Shemesh Shay | Chief Dev. & Ops. Officer |
May 10 '24 |
Buy |
6.32 |
1,113 |
7,034 |
1,493,068 |
BENTSUR RON | Chairman & CEO |
Mar 18 '24 |
Buy |
10.29 |
5,000 |
51,450 |
3,242,484 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):